Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2008 1
2009 2
2010 1
2011 2
2012 8
2013 13
2014 12
2015 12
2016 13
2017 15
2018 11
2019 10
2020 15
2021 18
2022 25
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
EANM guidelines for PET-CT and PET-MR routine quality control.
Koole M, Armstrong I, Krizsan AK, Stromvall A, Visvikis D, Sattler B, Nekolla SG, Dickson J; EANM Physics committee. Koole M, et al. Z Med Phys. 2023 Feb;33(1):103-113. doi: 10.1016/j.zemedi.2022.08.003. Epub 2022 Sep 24. Z Med Phys. 2023. PMID: 36167600 Free PMC article. Review.
Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients.
Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, Vandamme T, Serdons K, Koole M, Bormans G, Laenen A, Clement PM, Geboes K, Van Cutsem E, Nackaerts K, Stroobants S, Verslype C, Van Laere K, Deroose CM. Boeckxstaens L, et al. Among authors: koole m. EJNMMI Res. 2023 Jun 1;13(1):53. doi: 10.1186/s13550-023-01003-3. EJNMMI Res. 2023. PMID: 37261615 Free PMC article.
18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.
Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM. Pauwels E, et al. Among authors: koole m. J Nucl Med. 2023 Apr;64(4):632-638. doi: 10.2967/jnumed.122.264563. Epub 2022 Oct 20. J Nucl Med. 2023. PMID: 36265911 Free article.
Cognitive Decline Assessment: A Review From Medical Imaging Perspective.
Dartora CM, Borelli WV, Koole M, Marques da Silva AM. Dartora CM, et al. Among authors: koole m. Front Aging Neurosci. 2021 Aug 18;13:704661. doi: 10.3389/fnagi.2021.704661. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34489675 Free PMC article. Review.
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals.
Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, Koole M, Herth MM, Bardiès M, Martins AF, Paulo A, Lyashchenko SK, Todde S, Nag S, Lamprou E, Abrunhosa A, Giammarile F, Decristoforo C. Korde A, et al. Among authors: koole m. EJNMMI Radiopharm Chem. 2022 Jul 19;7(1):18. doi: 10.1186/s41181-022-00168-x. EJNMMI Radiopharm Chem. 2022. PMID: 35852679 Free PMC article. Review.
[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients.
Pauwels E, Celen S, Baete K, Koole M, Bechter O, Bex M, Renard M, Clement PM, Jentjens S, Serdons K, Van Laere K, Bormans G, Deroose CM. Pauwels E, et al. Among authors: koole m. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1134-1145. doi: 10.1007/s00259-022-06046-7. Epub 2022 Nov 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 36435928
147 results